AETHLON MEDICAL INC — Form 8-K
Filed November 12, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
On September 17, 2026, Aethlon Medical entered a merger agreement with North Immunology, Inc., under which Aethlon shareholders will receive contingent value rights (CVRs) tied to potential future monetization of the Hemopurifier business. The company implemented workforce reductions, retaining only key personnel for regulatory and Australian oncology trial management. Aethlon had $6.5M cash as of September 30, 2026, and reported Q2 FY2027 operating expenses of $2.7M (up 77.2% YoY), primarily driven by merger-related professional fees.
Why this rating
Merger represents business transformation and effective wind-down of legacy operations for $5.7M market-cap company. Shareholders face dilution via CVR contingency; merger execution risk is material; going-concern uncertainty pending close.
Tradability signal
NO TRADE
No trade: negative news, but this cell's evidence is too weak. Similar past filings (29 in this cell) moved -2.13% in the called direction over 4 hrs; shrunk for sample size that's a -1.14% edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $5.58 ▼ 1.06% | at our read · unknown $5.64 | +10 min · unknown $5.38 ▼ 4.61% | +30 min · unknown $5.23 ▼ 7.27% | +1 hr · unknown $5.29 ▼ 6.12% | +4 hrs · unknown $5.38 ▼ 4.65% |
The stock had already moved +1.08% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.